Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study

References

• World Health Organization. Blindness and vision impairment; 2019. Available from: https://www.who.int/news-room/fact-sheets/detail/blindness-and-visual-impairment. Accessed November 21, 2019.
   Google Scholar
• Park SJ, Lee JH, Woo SJ, et al. Age-related macular degeneration: prevalence and risk factors from Korean national health and nutrition examination survey, 2008 through 2011. Ophthalmology. 2014;121(9):1756–1765. doi:10.1016/j.ophtha.2014.03.022
   PubMed Web of Science ®Google Scholar
• Park SJ, Kwon K, Choi N-K, Park KH, Woo SJ. Prevalence and incidence of exudative age-related macular degeneration in South Korea: a nationwide population-based study. Ophthalmology. 2015;122(10):2063–2070.e1. doi:10.1016/j.ophtha.2015.06.018
   Web of Science ®Google Scholar
• Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration preferred practice pattern®. Ophthalmology. 2019;127(1):P1–P65. doi:10.1016/j.ophtha.2019.09.024
   Web of Science ®Google Scholar
• Cornel S, Adriana ID, Mihaela TC, et al. Anti-vascular endothelial growth factor indications in ocular disease. Rom J Ophthalmol. 2015;59(4):235–242.
   PubMedGoogle Scholar
• Novartis. Lucentis (ranibizumab) PFS Korean NPI; Published online 2019.
   Google Scholar
• Kim JH, Lee DW, Chang YS, Kim JW, Kim CG. Twelve-month outcomes of treatment using ranibizumab or aflibercept for neovascular age-related macular degeneration: a comparative study. Graefes Arch Clin Exp Ophthalmol. 2016;254(11):2101–2109. doi:10.1007/s00417-016-3353-7
   Web of Science ®Google Scholar
• Kang HM, Koh HJ. Long-term visual outcome and prognostic factors after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2013;156(4):652–660. doi:10.1016/j.ajo.2013.05.038
   Web of Science ®Google Scholar
• Shin JY, Yu HG. Optical coherence tomography-based ranibizumab monotherapy for retinal angiomatous proliferation in Korean patients. Retina. 2014;34(12):2359–2366. doi:10.1097/IAE.0000000000000225
   Web of Science ®Google Scholar
• Woo SJ, Cho GE, Cho JH. Short-term efficacy and safety of ranibizumab for neovascular age-related macular degeneration in the real world: a post-marketing surveillance study. Korean J Ophthalmol. 2019;33(2):150–166. doi:10.3341/kjo.2018.0081
   Google Scholar
• Holz FG, Figueroa MS, Bandello F, et al. Ranibizumab treatment in treatment-naive neovascular age-related macular degeneration: results From LUMINOUS, a Global Real-World Study. Retina. 2019. doi:10.1097/IAE.0000000000002670
   Web of Science ®Google Scholar
• Parikh R, Pirakitikulr N, Chhablani J, Sakurada Y, Singh RP, Modi YS. A multinational comparison of anti–vascular endothelial growth factor use: the United States, the United Kingdom, and Asia-Pacific. Opthalmol Retina. 2019;3(1):16–26. doi:10.1016/j.oret.2018.08.002
   PubMedGoogle Scholar
• Lotery A, Griner R, Ferreira A, Milnes F, Dugel P. Real-world visual acuity outcomes between ranibizumab and aflibercept in treatment of neovascular AMD in a large US data set. Eye (Lond). 2017;31(12):1697–1706. doi:10.1038/eye.2017.143
   PubMed Web of Science ®Google Scholar
• Khanani AM, Skelly A, Bezlyak V, Griner R, Torres LR, Sagkriotis A. SIERRA-AMD: a retrospective, real-world evidence study of patients with neovascular age-related macular degeneration in the USA. Opthalmol Retina. 2019;4(2):122–133. doi:10.1016/j.oret.2019.09.009
   Google Scholar
• American Society of Retina Specialist. 2019 global trends in retina survey; 2019. Available from: https://www.asrs.org/content/documents/2019-global-trends-survey-for-website.pdf. Accessed February 27, 2019.
   Google Scholar
• Mantel I, Gillies MC, Souied EH. Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration. Surv Ophthalmol. 2018;63(5):638–645. doi:10.1016/j.survophthal.2018.02.004
   Web of Science ®Google Scholar
• Hatz K, Prünte C. Polypoidal choroidal vasculopathy in caucasian patients with presumed neovascular age-related macular degeneration and poor ranibizumab response. Br J Ophthalmol. 2014;98(2):188–194. doi:10.1136/bjophthalmol-2013-303444
   Web of Science ®Google Scholar
• Levy J, Shneck M, Rosen S, et al. Intravitreal bevacizumab (avastin) for subfoveal neovascular age-related macular degeneration. Int Ophthalmol. 2009;29(5):349–357. doi:10.1007/s10792-008-9243-1
   Google Scholar
• Cohen SY, Mimoun G, Oubraham H, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina. 2013;33(3):474–481. doi:10.1097/IAE.0b013e31827b6324
   PubMed Web of Science ®Google Scholar
• Menon G, Chandran M, Sivaprasad S, Chavan R, Narendran N, Yang Y. Is it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial). Eye (Lond). 2013;27(8):959–963. doi:10.1038/eye.2013.93
   PubMed Web of Science ®Google Scholar
• Holz FG, Mitchell P, Macfadden W, Parikh S Treatment patterns in prior ranibizumab-treated patients with neovascular age-related macular degeneration: real-world outcomes from the LUMINOUSTM study. 18th EURETINA Congress; Published online 2018.
   Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419–1431. doi:10.1056/NEJMoa054481
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. doi:10.1056/NEJMoa062655
   PubMed Web of Science ®Google Scholar
• Chen S-N, Cheng C-K, Yeung L, et al. One-year real-world outcomes of ranibizumab 0.5 mg treatment in Taiwanese patients with polypoidal choroidal vasculopathy: a subgroup analysis of the REAL study. Int J Ophthalmol. 2018;11(11):1802–1808. doi:10.18240/ijo.2018.11.11
   PubMed Web of Science ®Google Scholar
• Holz FG, Tadayoni R, Beatty S, et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol. 2015;99(2):220–226. doi:10.1136/bjophthalmol-2014-305327
   PubMed Web of Science ®Google Scholar
• Eldem B, Lai TYY, Ngah NF, et al. An analysis of ranibizumab treatment and visual outcomes in real-world settings: the UNCOVER study. Graefes Arch Clin Exp Ophthalmol. 2018;256(5):963–973. doi:10.1007/s00417-017-3890-8
   PubMed Web of Science ®Google Scholar
• Providência J, Rodrigues TM, Oliveira M, et al. Real-world results of aflibercept versus ranibizumab for the treatment of exudative AMD using a fixed regimen. Biomed Res Int. 2018;2018:1–7. doi:10.1155/2018/9276580
   Web of Science ®Google Scholar
• Lim JH, Wickremasinghe SS, Xie J, et al. Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration. Am J Ophthalmol. 2012;153(4):678–686.e2. doi:10.1016/j.ajo.2011.09.013
   Web of Science ®Google Scholar
• Lanzetta P, Cruess AF, Cohen SY, et al. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies. Acta Ophthalmol. 2018;96(8):e911–e918. doi:10.1111/aos.13751
   Web of Science ®Google Scholar
• Regillo CD, Busbee BG, Ho AC, Ding B, Haskova Z. Baseline predictors of 12-month treatment response to ranibizumab in patients with wet age-related macular degeneration. Am J Ophthalmol. 2015;160(5):1014–1023.e2. doi:10.1016/j.ajo.2015.07.034
   Web of Science ®Google Scholar
• Ying G, Huang J, Maguire MG, et al. Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology. 2013;120(1):122–129. doi:10.1016/j.ophtha.2012.07.042
   PubMed Web of Science ®Google Scholar
• Zhang X, Lai TYY. Baseline predictors of visual acuity outcome in patients with wet age-related macular degeneration. Biomed Res Int. 2018. doi:10.1155/2018/9640131
   Web of Science ®Google Scholar
• Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144(6):850–857. doi:10.1016/j.ajo.2007.08.012
   PubMed Web of Science ®Google Scholar
• Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246–252. doi:10.1016/j.ophtha.2006.10.045
   PubMed Web of Science ®Google Scholar
• Pedrosa AC, Reis-Silva A, Pinheiro-Costa J, et al. Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes. Clin Ophthalmol. 2016;10:541–546. doi:10.2147/OPTH.S90913
   Google Scholar
• Wang F, Yuan Y, Wang L, et al. One-year outcomes of 1 dose versus 3 loading doses followed by pro re nata regimen using ranibizumab for neovascular age-related macular degeneration: the ARTIS Trial. J Ophthalmol. 2019;2019:1–6. doi:10.1155/2019/7530458
   Web of Science ®Google Scholar
• Koh A, Lai TYY, Wei WB, et al. Real-world effectiveness and safety of ranibizumab treatment in patients with and without polypoidal choroidal vasculopathy: twelve-Month Results From the LUMINOUS Study. Retina. 2019. doi:10.1097/IAE.0000000000002624
   Web of Science ®Google Scholar
• Woo SJ, Ahn J, Morrison MA, et al. Analysis of genetic and environmental risk factors and their interactions in Korean patients with age-related macular degeneration. PLoS One. 2015;10(7):e0132771. doi:10.1371/journal.pone.0132771
   PubMed Web of Science ®Google Scholar
• Laude A, Cackett PD, Vithana EN, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res. 2010;29(1):19–29. doi:10.1016/j.preteyeres.2009.10.001
   PubMed Web of Science ®Google Scholar
• Sakurada Y, Yoneyama S, Imasawa M, Iijima H. Systemic risk factors associated with polypoidal choroidal vasculopathy and neovascular age-related macular degeneration. Retina. 2013;33(4):841–845. doi:10.1097/IAE.0b013e31826ffe9d
   Web of Science ®Google Scholar